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Abnormalities and impairments in axonal transport are suggested to strongly contribute to
the pathological alterations underlying AD. The exact mechanisms leading to axonopathy
are currently unclear, but it was recently suggested that APP expression itself triggers
axonal degeneration. We used APP transgenic mice and crossed them on a hemi- or
homozygous PS1 knock-in background (APP/PS1KI). Depending on the mutant PS1
dosage, we demonstrate a clear aggravation in both plaque-associated and plaque-distant
axonal degeneration, despite of an unchanged APP expression level. Amyloid-β (Aβ)
peptides were found to accumulate in axonal swellings as well as in axons and apical
dendrites proximate to neurons accumulating intraneuronal Aβ in their cell bodies. This
suggests that Aβ can be transported within neurites thereby contributing to axonal deficits.
In addition, diffuse extracellular Aβ deposits were observed in the close vicinity of axonal
spheroids accumulating intracellular Aβ, which might be indicative of a local Aβ release
from sites of axonal damage.
Keywords: amyloid, presenilin, axonal degeneration, axonopathy, intraneuronal Abeta, transgenic mice,
Alzheimer, axonal transport
INTRODUCTION
Alzheimer’s disease (AD) is a severe neurodegenerative disorder
characterized by progressive cognitive decline representing the
main cause of dementia among the elderly population. Major
neuropathological hallmarks of AD include the deposition of
extracellular senile plaques, consisting of amyloid-β (Aβ) peptides
and the occurrence of neurofibrillary tangles, representing intra-
cellular accumulations of abnormal phosphorylated protein tau
(Selkoe, 2001). While the majority of all AD cases occurs sporad-
ically, a small percentage of familial early onset cases is caused
by mutations in either the amyloid-precursor protein (APP) or
the presenilin 1 (PS1) or presenilin 2 (PS2) genes. Most of these
mutations have been shown to elevate the levels of the patho-
logically relevant Aβ42 isoform, which is considered to cause
neurotoxicity and shows a tendency to aggregate very rapidly into
amyloid fibrils (Iwatsubo, 1998; St. George-Hyslop, 2000).
Impairments in axonal transport with the formation of axonal
spheroids have been reported in a variety of neurodegener-
ative diseases (Yagishita, 1978) and are suggested to strongly
contribute to the pathological alterations underlying AD (Roy
et al., 2005; Zhu et al., 2005; Stokin and Goldstein, 2006) and
other diseases like e.g., lysosomal storage disorders (Ohara et al.,
2004). Fundamental axonal pathology in AD includes the aber-
rant accumulation of various proteins in abnormal swollen axons,
including APP (Cras et al., 1991), synaptic proteins like alpha-
synuclein (Wirths et al., 2000), glycogen (Mann et al., 1987),
as well as the occurrence of abnormal paired helical filaments
(PHFs) (Praprotnik et al., 1996).With the implementation of new
imaging techniques, it has been recently shown in in-vivo studies
that impairment of axonal transport mechanisms and decreased
axonal transport rates might have a significant impact on the
pathogenesis of AD already early in the disease process (Smith
et al., 2003; Teipel et al., 2007; Cross et al., 2008; Minoshima and
Cross, 2008).
Indications for disturbances in axonal transport with con-
comitant axonopathy have been described in different APP-based
transgenic AD mouse models (Stokin et al., 2005; Salehi et al.,
2006; Wirths et al., 2006, 2007; Adalbert et al., 2009; Chen et al.,
2011; Jawhar et al., 2012). Surprisingly, it has been reported that
an increase in the Aβ42/Aβ40 ratio, as well as increased deposition
of Aβ peptides, resulted in a suppression of APP-induced axonal
deficits in transgenic mouse and Drosophila models, leading to
the suggestion that axonal defects are not caused by Aβ pep-
tides but depend entirely on APP expression levels (Stokin et al.,
2008). To investigate this further, we quantified axonal spheroids
in APP single transgenic and APP transgenic mice co-expressing
knocked-in mutant PS1 on endogenous levels in either a hemi-
(APP/PS1KIhe) or homozygous (APP/PS1KIho) manner in the
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present report. Aβ peptide levels were dramatically increased as
a function of PS1 knock-in gene dosage and led to a signifi-
cant aggravation of the axonal phenotype, despite of unchanged
APP expression levels. In addition, we provide evidence for a
functional relationship between intraneuronal accumulation of
Aβ peptides and the formation of plaque-distant axonal spheroids




The generation of APP/PS1KI mice has been described previously
(Casas et al., 2004). In brief, human mutant APP751 contain-
ing the Swedish and London mutations is overexpressed under
the control of the murine Thy-1 promoter, whereas murine PS1
with the M233T and L235P FAD-linked mutations is expressed
under the control of the endogenous mouse PS1 promoter. Mice
designated APP were hemizygous for the APP751SL transgene,
whereas in APP/PS1KIhe and APP/PS1KIho mice additionally
one or both endogenous wildtype PS1 alleles were replaced by
murine PS1 carrying the M233T and L235P mutations by a
knock-in strategy. Mice designated PS1KIho were homozygous for
the PS1 knock-in mutations without overexpression of human
APP. All mice were used at the age of 10 months. To obtain
APP/PS1KIhe/YFP-H transgenic mice, APP/PS1KIho mice were
crossed with homozygous YFP-H mice [line B6.Cg-Tg(Thy1-
YFPH)2Jrs/J, Charles River Laboratories], expressing the fluores-
cent protein YFP in a subset of neurons (Feng et al., 2000). All
animals were handled according to German guidelines for animal
care.
IMMUNOHISTOCHEMISTRY ON PARAFFIN SECTIONS
Mice were transcardially perfused with 4% paraformaldehyde
(PFA) in 0.01M phosphate buffered saline (PBS) and brains and
spinal cords were carefully dissected. Post fixation was carried
out in 4% buffered formalin at 4◦C before the tissue was embed-
ded in paraffin. Immunohistochemistry was performed on 4μm
paraffin sections, as described previously (Wirths et al., 2002). In
brief, sections were deparaffinized in xylene and rehydrated in an
ethanol series. After treatment with 0.3% H2O2 in PBS to block
endogenous peroxidases, antigen retrieval was achieved by boiling
sections in 0.01M citrate buffer pH 6.0, followed by 3min incuba-
tion in 88% formic acid. Non-specific binding sites were blocked
by treatment with skim milk and fetal calf serum in PBS prior to
the addition of the primary antibodies. The following antibodies
were applied: 4G8 (Covance, 1:10.000) (Christensen et al., 2008),
OC (generous gift of Glabe and Kayed, 1:1000) (Kayed et al.,
2007) and Aβ[N] (IBL, 1:500) (Christensen et al., 2010) against
Aβ, 22C11 (Millipore, 1:1000) and 23850 (generous gift of G.
Multhaup, 1:500) against human APP, G2-10 (Millipore, 1:500)
and Aβ40 (Synaptic Systems, #218203, 1:500) against Aβ40, Aβ42
(Synaptic Systems, #218703, 1:250), N3pE against pyroglutamate-
modified Aβ (American Research Products, 1:250) (Wirths et al.,
2009), kinesin light chain 1 (KLC1, Santa Cruz, sc-25735, 1:100)
as well as anti-NF-200 (Millipore, 1:1000) and an antibody
detecting phosphorylated APP at position T668 (anti-pT668;
Cell Signaling Technologies, 1:500). Primary antibodies were
incubated overnight in a humid chamber at room temperature
followed by incubation with biotinylated secondary antibod-
ies (DAKO). Staining was visualized using the ABC method
with Vectastain kit (Vector Laboratories) and diaminobenzidine
(DAB) as chromogen providing a reddish brown color. For double
staining, the procedure was repeated starting from blocking with
skim milk followed by incubation with the second primary anti-
body and ended by combining the ABC Vectastain kit with
Histogreen (Linaris) instead of DAB, providing a green color.
Counterstaining was carried out with hematoxylin. PS1KIho con-
trol mice were consistently negative for APP and Aβ staining.
WESTERN-BLOT
For immunoblotting, proteins were extracted in lysis buffer
(50mM Tris, 120mM NaCl, pH 8.0) and electrophoresis was
performed using 4–12% sodium dodecylsulfate-polyacrylamide
Variogels (Anamed) under denaturing conditions. Proteins were
transferred to nitrocellulose membranes (Amersham Pharmacia)
which were blocked with 10% skim milk in Tris buffer and blots
were probed with the monoclonal Aβ antibodyW0-2 (Millipore),
detecting full-length APP, C99, and Aβ peptides.
QUANTIFICATION OF Aβ LOAD
For each animal, three paraffin embedded sections at least 25μm
afar from each other were stained simultaneously with DAB as
chromogen using the 4G8 antibody (1:10.000). Quantification
of the Aβ load was performed using an Olympus BX-51 micro-
scope equipped with an Olympus DP-50 camera and the ImageJ
software [NIH, USA (Wayne Rasband. ImageJ. U.S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.
nih.gov/ij/, 1997–2013)], and was performed for 6 mice each
of the genotypes APP, APP/PS1KIhe, and APP/PS1ho. The area
fraction covered by Aβ staining was evaluated in the frontal
cortex providing a general measure of the Aβ accumulation.
Furthermore, the area covered by Aβ staining was evaluated in
pons and spinal cord where axonal pathology was quantified.
Representative 100x magnified images were systematically cap-
tured in each region. The area fraction calculation was based on
binarized images generated with ImageJ through a fixed intensity
threshold selective for the 4G8 DAB stain.
QUANTIFICATION OF PLAQUE-DISTANT AXONAL SWELLINGS
For each animal, two series of three paraffin embedded sections
at least 25μm afar were stained simultaneously using either the
NF-200 or the anti-pT668 antibodies with DAB as chromogen
together with the 4G8 antibody using Histogreen as chromogen.
Quantification of plaque-distant dystrophic fibers with a diam-
eter of >10μm was performed using the meander scan of
StereoInvestigator 7 (MicroBrightfield) and a BX51 microscope
(Olympus). On average, three sections were used for statisti-
cal analyses. Quantifications were performed in pons and spinal
cord because these regions had obvious dystrophic fiber pathol-
ogy together with moderate plaque pathology, making it possible
to distinguish plaque associated from plaque independent dys-
trophic neurites. Quantification was performed in 6 mice of each
of the genotypes APP, APP/PS1KIhe and APP/PS1KIho thus hav-
ing the same levels of the APP transgene but having varying PS1KI
gene dosages.
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CONFOCAL MICROSCOPY
APP/PS1KIhe/YFP-H mice were stained using the OC antibody
detecting Aβ fibrillar oligomers (Kayed et al., 2007). Images were
acquired with an AOBS-equipped Leica SP2 confocal laser scan-
ning microscope (Leica Microsystems, Mannheim, Germany)
using a 63×/1.4 oil-immersion objective. Sequential, line-by-line
405, 514, and 561 nm laser scans were applied to collect the
respective DAPI (410–480 nm), YFP (520–550 nm), and Alexa
Fluor 568 (580–650 nm) emissions. The ImageJ software package
was then used to view and process the resulting images with a
noise-reducing, median filter.
REAL TIME-PCR
For real-time RT-PCR analysis, 10-month-old male mice (n = 4
per group) were used. In brief, frozen brain hemispheres were
homogenized in 1ml of TriFast reagent (Peqlab) per 100mg tis-
sue using a glass-teflon homogenizer (10 strokes, 800 rpm). RNA
extraction and DNAse digestion was performed according to the
protocol of the manufacturer. Reverse transcription of the puri-
fied RNA samples was carried out using the First Strand cDNA
Synthesis Kit (ThermoFisher). RT-PCR was performed using a
Stratagene MX3000P Real-Time Cycler. The SYBR-green based
FastStart Universal SYBR Green (Roche) containing ROX as an
internal reference dye was used for amplification. The following
primer sets were used: KLC1-for: CTTCCTCCCCTCCGTCAG,
KLC1-rev: AAATGACCCTGAGAGCATGG; KIF1A-for: ACC
GCCACCTTCACAGAG, KIF1A-rev: CTATCCCCAGTGACG
CCTG; KIF5A-for: GGACGTCTTTGACGATCTGC, KIF5A-rev:
GGGACGACAGCGTCATTATT. Relative expression levels were
calculated using the 2−Ct method (Livak and Schmittgen,
2001). Expression levels were normalized to the housekeep-
ing gene β-Actin and calibrated to average expression level of
untreated wild type animals for each gene (Hillmann et al., 2012).
STATISTICAL ANALYSIS
Dystrophic fiber quantifications and Aβ area percentages were
analyzed using One-Way ANOVA followed by t-tests. Data are
presented as mean ±s.e.m. Significance levels were given as fol-
lows: ∗∗∗P < 0.001; ∗∗P < 0.01; ∗P < 0.05. All statistical analysis
was performed using GraphPad Prism version 4.03 for Windows
(GraphPad Software, San Diego, CA, USA).
RESULTS
ANALYSIS OF APP EXPRESSION LEVELS AND Aβ LOAD WITH
INCREASING MUTANT PS1 GENE DOSAGE
Staining with antibodies against human APP revealed approxi-
mately equal numbers of APP-positive cells in APP, APP/PS1KIhe,
and APP/PS1KIho mice at 10 months of age with comparable
staining intensity, but with dystrophic fibers accumulating APP in
APP/PS1KIhe and APP/PS1KIho mice (Figures 1A–C). Western-
blot analysis confirmed that the overall expression of human full-
length APP in the three mouse lines was comparable with no con-
siderable variation between the different genotypes. In contrast,
the levels of the β-secretase cleavage product C99, as well as Aβ,
increased with incremental mutant PS1 gene dosage (Figure 1D).
To assess the influence of varying gene doses of PS1 on Aβ
levels, Aβ plaque pathology was quantified in the frontal cortex,
FIGURE 1 | Immunostaining of human APP using 22C11 in spinal cords
of APP (A), APP/PS1KIhe (B), and APP/PS1KIho (C) mice showing
comparable numbers of APP-expressing cells in all three genotypes.
Western-blot analyses using W0-2 revealed no differences in the amount of
human full-length APP among the three genotypes, however, the levels of
C99 and Aβ increased with increasing PS1KI gene dosage (D). Scale bar:
50μm.
pons and spinal cords of 10-month-old APP, APP/PS1KIhe, and
APP/PS1KIho mice using computer-assisted analysis of 4G8 DAB
stained sections (Figure 2). Only very minor amounts of Aβ
were observed in the pons and spinal cords of APP transgenic
mice harboring no PS1KI mutations (Figures 2E,H,I,L), whereas
3.9% of the frontal cortex were covered by Aβ (Figures 2A,D).
Introducing one PS1KI allele to generate APP/PS1KIhe mice
resulted in a significant increase in the Aβ load in the frontal
cortex by 80% leading to an overall Aβ load of 7% (Figure 2A).
In good agreement, significant Aβ amounts were observed in
the pons and spinal cord which had Aβ loads of 3.6 and 3.3%,
respectively (Figures 2F,H,J,L). A further increase in the PS1KI
gene dosage resulting in the APP/PS1KIho mice caused another
approximate doubling of the Aβ load in all three regions mea-
sured (Figures 2C,D,G,H,K,L), whereas PS1KIho mice were con-
sistently negative for 4G8 staining (data not shown). The intro-
duction of one or two copies of mutant PS1 under the control of
its endogenous promoter therefore strongly aggravates extracel-
lular Aβ pathology.
PHOSPHORYLATED APP (pAPP) AS A MARKER FOR DYSTROPHIC
NEURITES AND AXONAL SPHEROIDS
APP represents a widely used marker for the detection of axonal
pathology e.g., in the analysis of traumatic brain injury (TBI)
(Pierce et al., 1996), which has also been previously used to detect
axonal degeneration in APP/PS1KIho mice (Wirths et al., 2007).
However, one of the problems of using APP antibodies in the
analysis of axonal degeneration in APP-transgenic mouse models
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FIGURE 2 | Immunostaining of Aβ using 4G8 antibody in 10-month-old
APP, APP/PS1KIhe, and APP/PS1KIho mice in frontal cortex (A–C), pons
(E–G), and spinal cord (I–K) together with respective quantifications of
the area covered by Aβ staining (D,H,L). Virtually no Aβ peptide
accumulation was detected in the pons and spinal cord of APP mice,
whereas about 4% of the frontal cortical area was covered by Aβ staining.
Upon introduction of one PS1KI gene (APP/PS1KIhe mice), the accumulation
of Aβ was found to rise significantly in all three regions investigated and
further approximately doubled with the introduction of an additional PS1KI
gene (APP/PS1KIho mice), reaching percentile Aβ covered areas of 14, 8, and
6.5% in the frontal cortex, pons, and spinal cord, respectively. Data was
analyzed from 6 mice of each genotype and analyzed using One-Way ANOVA
followed by t-tests. All error bars represent mean ±s.e.m. ∗∗∗P < 0.001;
∗∗P < 0.01; ∗P < 0.05. Scale bar: 200μm.
is the very broad staining pattern. This includes cell bodies, axonal
swellings, and dystrophic neurites in the vicinity of amyloid
plaques, thereby complicating the analysis of distinct patholog-
ical alterations like axonal pathology especially in plaque-rich
brain areas. By using an antibody which detects phosphorylated
APP T668 (anti-pT668), no staining of cell somata, but only
plaque-associated dystrophic neurites, as well as large plaque-
distant axonal swellings could be detected. Staining of adjacent
sections with antibodies detecting an N-terminal epitope of APP
(Figures 3A,C,E,G,I,K) and anti-pT668 (Figures 3B,D,F,H,J,L)
revealed a complete overlap of plaque-associated neurites and iso-
lated axonal spheroids. APP phosphorylated at position 668 is
localized mainly in axonal processes, as is evident in the mossy
fibers of the hippocampus (Figures 3F,H), in contrast to APP
which is mainly found in the somatodendritic compartment
(Figures 3E,G). Double-immunofluorescent staining revealed a
nice co-localization in axonal spheroids (Figures 3K–M). The
use of pAPP antibodies strongly facilitates the quantification of
axonal spheroids as it represents an excellent marker labeling only
axonal processes without concomitant staining of cell bodies.
QUANTIFICATION OF DYSTROPHIC FIBERS WITH VARYING PS1KI GENE
DOSAGE
The number of plaque-distant axonal swellings with a diame-
ter of larger than 10μm was quantified in the pons and spinal
cord using antibodies towards pAPP (anti-pT668) and neuro-
filament (NF-200) as markers of axonopathy. This was done in
double-stainings together with 4G8 visualizing Aβ plaques in 10-
month-old APP, APP/PS1KIhe, and APP/PS1KIho mice in the
pons (Figures 4A–C) and spinal cord (Figures 4E–G), to ensure
that only plaque-distant axonal spheroids were counted. The
quantification showed practically no axonal swellings in the pons
and spinal cord of APP single transgenic mice with either NF-
200 (Figures 4I–K) or anti-pT668 (Figures 4L–N). In contrast,
a considerable amount of dystrophic fibers was found in the
APP/PS1KIhe mice using both NF-200 and anti-pT668 in pons
as well as spinal cord, where the increase was found in both
gray and white matter, leading to an even further increase in
APP/PS1KIho mice (Figure 4). No dystrophic fibers were found
in PS1KIho (Figures 4D,H) or wildtype control mice (not shown).
Thus using the two markers NF-200 and anti-pT668, the amount
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FIGURE 3 | Comparison between APP (22C11) and phosphorylated
APP (pAPP668) staining patterns using parallel sections in
different brain regions of APP/PS1KIho mice of different ages.
Whereas 22C11 stains dystrophic neurites as well as cell bodies,
pAPP668 exclusively stains axonal compartments in cortex (A,B: 2m),
CA1 (C,D: 2m), hippocampal mossy fibers (E,F: 2m; G,H: 10m; I,J:
14m). Double-immunofluorescent staining of 22C11 (K) and pAPP668
(L) shows a high co-localization in axonal swellings (M). Arrowheads
indicate same plaques (C,D) or axonal swellings (I,J). Scale bars:
(A–H): 100μm; (I,J): 33μm; (K–M): 20μm.
of dystrophic fibers was found to rise proportionally to the dosage
of the mutant PS1KI gene in APP transgenic mice, however, this
type of pathological alterations is completely lacking in mice
harboring the PS1KIho gene alone.
LINKAGE OF INTRANEURONAL AND INTRAAXONAL ACCUMULATION
OF Aβ PEPTIDES
The directly proportional rise in Aβ load observed with increas-
ing PS1KI gene dosage in mice hemizygous for the APP transgene
also relates to intraneuronal Aβ, as exemplified in motor neurons
of the spinal cord (Figures 5A–C). In addition, axonal spheroids
in APP/PS1KIhe and APP/PS1KIho mice stained positive with
either 4G8 (Figures 6A,B), Aβ[N] (Figure 6C) or end-specific
antibodies detecting neo-epitopes against Aβ40 at the C-terminus
(Figure 6D) and AβN3pE at the N-terminus (Figure 6E) of Aβ,
while we were unable to detect Aβ42-positive axonal spheroids,
which might be due to a lower sensitivity of the used antibody
in stainings using paraffin-embedded material (data not shown).
To assess whether APP C-terminal fragments (CTFs) were present
in axonal spheroids, we performed double-stainings using N- and
C-terminal APP-specific antibodies.We detected a complete over-
lap, making it difficult to draw conclusions about the presence
of APP C-terminal fragments only, as full-length APP is highly
abundant in axons (data not shown). Using a combination of
anti-pT668 and 4G8 (Figure 6F) or NF-200 and 4G8 (Figure 6G)
in a conventional double-labeling, Aβ could be detected in the
close vicinity of plaque-distant axonal spheroids (arrowheads),
which might indicate that axonal swellings are able to release Aβ
peptides locally. Such a mechanism would be supported by the
analysis of APP/PS1KIhe/YFP-H mice by confocal imaging. Using
the OC antibody recognizing fibrillar Aβ oligomers, an accumu-
lation of Aβ inside and in the close vicinity of large plaque-distant
axonal spheroids was detected, although the axonal origin of
the extracellular Aβ cannot be definitely proven by the applied
methodology (Figures 7A–C).
In general, many plaque-distant swollen axonal processes were
found to accumulate Aβ, showing a scattered staining of Aβ-
positive granules throughout the lumen (Figures 7D–F). The
same pattern could also be detected in large dystrophic neurites
in the vicinity of plaques (Figures 7G–I). Abundant accumula-
tion of oligomeric intraneuronal Aβ inside cell bodies, especially
in the cortex, was confirmed using the OC antibody, where
Aβ granules were also observed in the axon (Figure 8A) and
large apical dendrite (Figure 8B) projecting from cells, indi-
cating that Aβ can be transported into axons as well as den-
drites. Occasionally, axonal swellings accumulating oligomeric
Aβ could be found directly connected to cortical neurons accu-
mulating abundant amounts of intraneuronal Aβ at the axon
hillock (Figures 8C,D). This might indicate that the Aβ accumu-
lating in large plaque-distant axonal spheroids originates from
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FIGURE 4 | Double ABC-immunostaining showing Aβ in blue using
4G8 antibodies together with visualization of fibers in reddish brown
using either NF-200 or anti-pT668. The number of plaque-distant
dystrophic neurites (black arrowheads) was found to increase with PS1KI
gene dosage; examples of stainings from APP, APP/PS1KIhe,
APP/PS1KIho, as well as PS1KIho mice are shown using the NF-200
antibody in the pons (A–D) and anti-pT668 antibody in the spinal cord
(E–H). Increasing numbers of NF-200 (I–K) as well as pT668-positive
(L–N) plaque-distant dystrophic fibers were found with increasing PS1
gene dosage in both pons and spinal cord with practically no dystrophic
fibers in the APP mice. All error bars represent mean ±s.e.m.
∗∗∗P < 0.001; ∗∗P < 0.01; ∗P < 0.05. Scale bar: 100μm.
neuronal cell bodies from where it becomes axonally transported.
We additionally performed stainings of kinesin light chain 1
(KLC1) which has been previously linked to axonal transport
of APP (Kamal et al., 2000). KLC1-positive axonal spheroids
were detected in APP/PS1KIhe and APP/PS1KIho mice, being
most abundant in the latter genotype (Figures 9A,B). We further
analyzed brain mRNA expression levels of several components
of the axonal transport machinery including KLC1 and kinesin
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FIGURE 5 | Intraneuronal Aβ accumulation (detected by 4G8, arrowheads) in the spinal cord was found to rise proportionally with increasing PS1KI
gene dosage in 10-month-old APP (A), APP/PS1KIhe (B), and APP/PS1KIho mice (C). Scale bar: 50μm.
FIGURE 6 | Aβ-positive axonal swellings (arrows) (A–C). Axonal
swellings were stained with 4G8 (A,B), Aβ[N] (C) or end-specific antibodies
detecting Aβ40 (D) or AβN3pE (E). Double immunostaining of Aβ (4G8,
blue) together with either anti-pT668 (F) or NF-200 (G) (reddish brown).
Small Aβ deposits (black arrowheads) could occasionally be detected in the
vicinity of large dystrophic neurites in both APP/PS1KIhe and APP/PS1KIho
mice. Scale bar: (A–C): 50μm; (D,E): 33μm; (F,G): 12.5μm.
family members KIF1A and KIF5A. Whereas no significant dif-
ferences were detected in KLC1 mRNA levels, both KIF1A (P <
0.05) and KIF5A levels (P < 0.01) were reduced in APP/PS1KIho
mice in comparison to PS1KIho mice harboring the same PS1
knock-in mutation in the absence of human APP expression and
Aβ accumulation (Figure 9C).
DISCUSSION
Axonal deficits and impairment of motor performance are com-
mon pathological alterations in mouse models expressing differ-
ent isoforms of human mutant tau protein (reviewed in Wirths
and Bayer, 2008). However, in recent years, similar phenotypes
have been reported for AD mouse models based on APP overex-
pression (Stokin et al., 2005; Wirths et al., 2006, 2007; Adalbert
et al., 2009; Jawhar et al., 2012) and disturbances of axonal trans-
port rates have been reported in APP-based transgenic mouse
models of Down syndrome (Salehi et al., 2003) and AD (Smith
et al., 2007; Kim et al., 2011; Wang et al., 2012). Accordingly, APP
has been demonstrated to undergo fast axonal transport (Koo
et al., 1990), presumably by a kinesin-I-mediated mechanism
(Kamal et al., 2000), and the β-site cleaving enzyme (BACE) and
PS1 have been shown to be associated with APP-resident mem-
branous cargos. This implies that Aβ can be produced directly
within axons (Kamal et al., 2001), however, this finding has been
questioned by others (Lazarov et al., 2005). In support of this
hypothesis, APP, BACE, PS1, and caspase-3 were found to co-
accumulate in swollen axons following traumatic brain injury
(Chen et al., 2004).
It has been suggested that axonopathies in APP-transgenic
mouse models entirely depend on APP overexpression with co-
expression of FAD-linked PS1 mutants, leading to increased Aβ
levels, thereby suppressing axonal defects (Stokin et al., 2008).
This observation prompted us to analyze axonal degeneration in
the APP/PS1KIho mouse model, as well as in APP single trans-
genic and APP/PS1KIhe mice, all expressing the same APP trans-
genic construct at equal levels. Previous work in the APP/PS1KIho
mouse model has demonstrated a severe age-dependent axonal
degeneration phenotype, which is characterized by the accumula-
tion of large axonal swellings (Wirths et al., 2007). These swellings
were most abundant in fiber-rich regions of the central ner-
vous system such as corpus callosum, pons, medulla and spinal
cord. We demonstrated a significant increase in these swellings
between 6 and 10 months of age, which only marginally wors-
ened at the age of 14 months (Wirths et al., 2007). The mice used
in the present study are based on Thy1-driven overexpression
of APP751 with the Swedish and London mutations and carry
either no (APP), one (APP/PS1KIhe), or two (APP/PS1KIho)
mutant murine PS1 alleles under the control of the endogenous
PS1 promoter (PS1 “knock-in,” PS1KI). Using this strategy, we
ensured that the APP expression levels did not differ between
the mouse lines, which we confirmed by immunostaining and
western-blotting using APP antibodies. However, the amount of
Aβ peptides and APP C-terminal fragment levels differs signif-
icantly between the analyzed mouse lines, leading to dramatic
increases in the Aβ load, comprising plaques as well as intraneu-
ronal Aβ, as a function of mutant PS1KI gene dosage. It has been
previously shown that expression of mutant PS1 alleles in com-
bination with the APP transgene does not only lead to a higher
overall Aβ load, but in addition causes a significant rise in the
Aβ42/Aβ40-total ratio and an earlier plaque onset (6m in APP
vs. 2m in APP/PS1KIho mice) (Casas et al., 2004).
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FIGURE 7 | Confocal images of fibrillar Aβ oligomers and Aβ fibrils (OC
antibody, red) accumulating in large dystrophic fibers (YFP, green) of
6-month-old YFP/APP/PS1KIhe mice with DAPI counterstaining
confirming the lack of nuclei (blue). Merged images are shown (A,D,G)
together with the isolated OC (B,E,H), and DAPI staining (C,F, I). Extracellular
accumulation of Aβ (White arrowhead) could be detected near large
dystrophic fibers accumulating intracellular Aβ (A–C). The intracellular
accumulation of intracellular granules of OC-stained Aβ peptides were
observed in many large dystrophic neurites, both plaque-distant (D–F) as well
as occasionally in the vicinity of plaques (G–I). (A–C) are generated as a
maximum projection of 20 confocal images within the dystrophic fibers,
whereas (D–I) are images of a single confocal plane. Scale bars: 10μm.
To facilitate quantification of axonal defects we introduced
APP phosphorylated at threonine 668 as a novel marker for
axonal spheroids and demonstrated that the detected axonal
swellings perfectly overlap with APP, a widely used marker for
axonal degeneration that is employed in routine neuropatholog-
ical analysis. In contrast to APP, which is abundantly present in
the somato-dendritic compartment of neurons, pAPP has been
predominantly detected in neuritic processes, including axonal
spheroids, as well as mossy fibers. This corroborates previous
studies, as pAPP has been previously shown to be present pre-
dominantly in neurites and growth cones of PC12 cells (Ando
et al., 1999), as well as in dystrophic neurites decorating senile
plaques in APP transgenic mice (Shin et al., 2007). Using double-
immunofluorescent stainings with N- and C-terminal APP anti-
bodies, a complete overlap was detected in axonal spheroids,
making it impossible to draw conclusions about the sole presence
of APP CTFs. The Aβ[N] antibody detects the N-terminus of Aβ
(aspartate at position 1) and it might therefore be assumed that
this antibody is also capable of detecting APP CTFs. However, we
have previously demonstrated that no immunoreactivity could be
detected in a mouse model overexpressing APP CTFs (SPA4CT
mice), which strongly argues against a cross-reactivity, confirm-
ing that the Aβ[N] antibody detects only Aβ peptides using
immunohistochemical methods (Christensen et al., 2010).
Upon quantification of pAPP, as well as NF-200-positive
axonal swellings distant from plaques in the pons and spinal
cord, significant increases in the numbers of dystrophic spheroids
were detected in APP/PS1KIhe mice, compared to APP sin-
gle transgenic mice which were almost devoid of any axonal
swellings in the analyzed regions. Comparison of APP/PS1KIhe
with APP/PS1KIho revealed a further 2–4 times increase of
spheroids in both pons and spinal cord.
This result is in apparent contradiction to the published find-
ing that the level of axonal defects was unchanged or even
suppressed in mice expressing mutant PS1 in combination with
mutant APP (Stokin et al., 2008). One major difference between
the APP/PS1 double-transgenic mice used in this report and our
mousemodel is the fact that the endogenousmurine PS1 gene was
still present in the APP/PS1 transgenic mice, whereas it had been
sequentially replaced by the FAD mutant form in the APP/PS1KI
model used in the present study. On the other hand, APP/PS1KIhe
mice still harbor one copy of endogenous PS1 but already show
a dramatic aggravation of the axonal degeneration phenotype.
It has been hypothesized that kinesin-based axonal transport is
compromised by mutations in PS1 via interaction with glycogen
synthase kinase 3β (GSK3β) and it has been further demonstrated
that the relative levels of GSK3β activity were increased in the
presence of mutant PS1, as well as in the absence of wildtype
PS1, resulting in increased phosphorylation of kinesin-light chain
and reduced anterograde transport (Pigino et al., 2003). In addi-
tion, anterograde fast axonal transport of APP and Trk receptors
is impaired in the sciatic nerve of mice expressing FAD-linked PS1
mutations, resulting in an increased phosphorylation of tau and
neurofilaments in the spinal cord (Lazarov et al., 2007). We were
able to demonstrate KLC1 accumulations in APP/PS1KIhe and
APP/PS1KIho mice, whereas PS1KIho or APP single transgenic
mice were completely devoid of KLC1-positive axonal swellings.
This implies that Aβ accumulation plays a critical role in the
development of the axonal phenotype in contrast to the pure
presence of mutant APP or mutant PS1. This is corroborated by
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 139 | 8
Christensen et al. PS1-dependent axonal degeneration in AD mice
FIGURE 8 | Confocal images of intraneuronal Aβ accumulation in
cortical neurons of 6-month-old YFP/APP/PS1KIhe mice. Aβ
accumulated inside cell bodies at the axon hillock (A,B), as well as in axons
(A, arrowhead) and large apical dendrites (B, arrowhead) projecting from
the cell body (OC antibody, red). Also, axonal swellings accumulating
intracellular Aβ were found directly connected to cortical neurons
accumulating abundant amounts of intraneuronal Aβ at the axon hillock
(Aβ[N] antibody, red) (C,D: enlargement of C). Scale bars: (A,B,D): 10μm;
(C): 40μm.
the reduced KIF1A and KIF5A mRNA levels indicating axonal
transport alterations in APP/PS1KIho mice.
In contrast to a major role for APP in the development of
axonal degeneration, our data is more consistent with a major
influence of Aβ peptides resulting in the abovementioned phe-
notype. Previous studies have linked Aβ peptides with axonal
transport deficits (e.g., Vossel et al., 2010) and recently espe-
cially oligomeric Aβ peptides have been linked to impaired axonal
transport. In good agreement with our finding of oligomeric
intracellular Aβ in axonal spheroids and respective neuronal cell
bodies, Pigino and colleagues have demonstrated that intraneu-
ronal oligomeric Aβ, but not unagreggated or fibrilar Aβ species,
compromises retrograde and anterograde fast axonal transport in
isolated squid axoplasm in nanomolar concentrations. This has
beenmechanistically linked to activation of casein kinase 2 (CK2),
which in turn leads to increased phosphorylation of kinesin-1
light chains (KLC1) and subsequent release of kinesin from its
cargoes (Pigino et al., 2009). Moreno and co-workers demon-
strated that nanomolar concentrations of intraaxonal oligomeric
(o)Aβ42, but not oAβ40 or extracellular oAβ42, acutely inhibited
synaptic transmission (Moreno et al., 2009). In addition, recent
studies implying primary hippocampal neurons demonstrated a
FIGURE 9 | KLC1-positive axonal spheroids (arrows) in 10-month-old
APP/PS1KIhe (A) and APP/PS1KIho mice (higher magnification of
spheroid indicated by arrowhead in inset). RT-PCR analysis of brain
mRNA levels of kinesin family members revealed significantly reduced
expression of KIF1A (p < 0.05) and KIF5A (p < 0.01) in APP/PS1Kiho mice
compared to PS1KIho control mice (C). All error bars represent mean
±s.e.m. ∗∗P < 0.01; ∗P < 0.05. Scale bar: (A,B):100μm
marked decrease in axonal trafficking of dense-core vesicles and
mitochondria in the presence of oligomeric Aβ (Decker et al.,
2010). Furthermore, Aβ peptides were found to accumulate in
axonal swellings distant from plaques, as well as in the vicinity
of plaques, raising the possibility that these swellings precede and
contribute to the formation of extracellular Aβ deposits. YFP-
H mice express the fluorescent protein YFP under the control
of the murine Thy1 promoter in a subset of cortical and hip-
pocampal neurons (Feng et al., 2000) and greatly facilitated the
tracking of neuronal processes from their respective cell bodies
(Beirowski et al., 2004; Adalbert et al., 2009) in the present study.
Aβ-positive granules were also detected in the axons and apical
dendrites of cortical neurons, leading to the assumption that Aβ
can be transported within fibers. It has been hypothesized that
if Aβ generation occurs at the sites of axonal blockage, amyloid
deposition might be due to focally increased Aβ secretion or lysis
of axonal spheroids that were enriched in Aβ peptides (Stokin
et al., 2005). Consistent with this hypothesis, Xiao and co-workers
have demonstrated by post-mortem tracing in human AD brains,
that tracer staining was observed around swollen axons, a type
of axonopathy, referred to as “axonal leakage.” In these leaking
axons, the tracer staining was observed in both intra-axonal and
extra-axonal spaces and even in the myelin sheath, while it was
restricted to the intra-axonal space in intact axons (Xiao et al.,
2011). Our finding of Aβ accumulation in fibers together with
diffuse extracellular Aβ deposits in the close vicinity of axonal
spheroids might add further evidence to the hypothesis that Aβ
can be released from fiber swellings, however more research is
needed to substantiate such a mechanism. It has been demon-
strated that Aβ-induced neuronal dysfunction can progress from
the neurons in the entorhinal cortex that selectively overexpress
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amyloid precursor protein (APP) to the terminal end of the den-
tate gyrus in a trans-synaptic manner (Harris et al., 2010). In
addition, Aβ reduces the number of spines and inhibits synaptic
plasticity in neurons that neighbor neurons overexpressing APP
(Wei et al., 2010). Finally, microinjections into electrophysiolog-
ically defined primary hippocampal rat neurons demonstrated
the direct neuron-to-neuron transfer of soluble oligomeric Aβ
followed by subsequent cytotoxicity (Nath et al., 2012). Taken
together, there is ample evidence that intracellular and in partic-
ular intraxonal Aβ peptides might play in important role in the
neurodegenerative processes underlying AD.
ACKNOWLEDGMENTS
The generous gift of the OC antibody from Dr. Charles Glabe
and Dr. Rakez Kayed, as well as of antiserum 23850 from
Dr. Gerd Multhaup is gratefully acknowledged. This work was
supported by the Alzheimer Forschung Initiative e.V. (Grant
#12802 to Oliver Wirths). We acknowledge support by the
Open Access Publication Funds of the Georg-August-University
Goettingen.
REFERENCES
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner,
M., et al. (2009). Severely dystrophic axons at amyloid plaques remain
continuous and connected to viable cell bodies. Brain 132, 402–416. doi:
10.1093/brain/awn312
Ando, K., Oishi, M., Takeda, S., Iijima, K., Isohara, T., Nairn, A. C., et al. (1999).
Role of phosphorylation of Alzheimer’s amyloid precursor protein during
neuronal differentiation. J. Neurosci. 19, 4421–4427.
Beirowski, B., Berek, L., Adalbert, R., Wagner, D., Grumme, D. S., Addicks, K., et al.
(2004). Quantitative and qualitative analysis of Wallerian degeneration using
restricted axonal labeling in YFP-H mice. J. Neurosci. Methods 134, 23–35. doi:
10.1016/j.jneumeth.2003.10.016
Casas, C., Sergeant, N., Itier, J. M., Blanchard, V., Wirths, O., Van Der Kolk, N.,
et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal
truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J.
Pathol. 165, 1289–1300. doi: 10.1016/S0002-9440(10)63388-3
Chen, H., Epelbaum, S., and Delatour, B. (2011). Fiber Tracts anomalies in
APPxPS1 transgenic mice modeling Alzheimer’s disease. J. Aging Res. 2011,
281274. doi: 10.4061/2011/281274
Chen, X. H., Siman, R., Iwata, A., Meaney, D. F., Trojanowski, J. Q., and Smith, D.
H. (2004). Long-term accumulation of amyloid-beta, beta-secretase, presenilin-
1, and caspase-3 in damaged axons following brain trauma. Am. J. Pathol. 165,
357–371. doi: 10.1016/S0002-9440(10)63303-2
Christensen, D. Z., Kraus, S. L., Flohr, A., Cotel, M. C., Wirths, O., and Bayer, T. A.
(2008). Transient intraneuronal Abeta rather than extracellular plaque pathol-
ogy correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta
Neuropathol. 116, 647–655. doi: 10.1007/s00401-008-0451-6
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., and Wirths,
O. (2010). Accumulation of intraneuronal Abeta correlates with ApoE4 geno-
type. Acta Neuropathol. 119, 555–566. doi: 10.1007/s00401-010-0666-1
Cras, P., Kawai, M., Lowery, D., Gonzalez-Dewhitt, P., Greenberg, B., and Perry,
G. (1991). Senile plaque neurites in Alzheimer disease accumulate amy-
loid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 88, 7552–7556. doi:
10.1073/pnas.88.17.7552
Cross, D. J., Flexman, J. A., Anzai, Y., Maravilla, K. R., and Minoshima, S. (2008).
Age-related decrease in axonal transport measured by MR imaging in vivo.
Neuroimage 39, 915–926. doi: 10.1016/j.neuroimage.2007.08.036
Decker, H., Lo, K. Y., Unger, S. M., Ferreira, S. T., and Silverman, M. A. (2010).
Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA
receptor-dependent mechanism that is mediated by glycogen synthase kinase
3beta in primary cultured hippocampal neurons. J. Neurosci. 30, 9166–9171.
doi: 10.1523/JNEUROSCI.1074-10.2010
Feng, G., Mellor, R. H., Bernstein, M., Keller-Peck, C., Nguyen, Q. T., Wallace, M.,
et al. (2000). Imaging neuronal subsets in transgenic mice expressing multiple
spectral variants of GFP. Neuron 28, 41–51. doi: 10.1016/S0896-6273(00)
00084-2
Harris, J. A., Devidze, N., Verret, L., Ho, K., Halabisky, B., Thwin, M. T., et al.
(2010). Transsynaptic progression of amyloid-β-induced neuronal dysfunc-
tion within the entorhinal-hippocampal network. Neuron 68, 428–441. doi:
10.1016/j.neuron.2010.10.020
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H. U., Bulic, B.,
et al. (2012). No improvement after chronic ibuprofen treatment in the 5XFAD
mouse model of Alzheimer’s disease. Neurobiol. Aging 33, 833.e839–833.e850.
doi: 10.1016/j.neurobiolaging.2011.08.006
Iwatsubo, T. (1998). Abeta42, presenilins, and Alzheimer’s disease.Neurobiol. Aging
19, S11–S13. doi: 10.1016/S0197-4580(98)00027-X
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., and Wirths, O. (2012).
Motor deficits, neuron loss, and reduced anxiety coinciding with axonal
degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse
model of Alzheimer’s disease. Neurobiol. Aging 33, 196.e129–196.e140. doi:
10.1016/j.neurobiolaging.2010.05.027
Kamal, A., Almenar-Queralt, A., Leblanc, J. F., Roberts, E. A., and Goldstein, L. S.
(2001). Kinesin-mediated axonal transport of a membrane compartment con-
taining beta-secretase and presenilin-1 requires APP. Nature 414, 643–648. doi:
10.1038/414643a
Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H., and Goldstein, L. S. (2000).
Axonal transport of amyloid precursor protein is mediated by direct bind-
ing to the kinesin light chain subunit of kinesin-I. Neuron 28, 449–459. doi:
10.1016/S0896-6273(00)00124-0
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., et al. (2007).
Fibril specific, conformation dependent antibodies recognize a generic epitope
common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar
oligomers. Mol. Neurodegener. 2, 18. doi: 10.1186/1750-1326-2-18
Kim, J., Choi, I. Y., Michaelis, M. L., and Lee, P. (2011). Quantitative in vivo
measurement of early axonal transport deficits in a triple transgenic mouse
model of Alzheimer’s disease using manganese-enhanced MRI. Neuroimage 56,
1286–1292. doi: 10.1016/j.neuroimage.2011.02.039
Koo, E. H., Sisodia, S. S., Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther,
K., et al. (1990). Precursor of amyloid protein in Alzheimer disease undergoes
fast anterograde axonal transport. Proc. Natl. Acad. Sci. U.S.A. 87, 1561–1565.
doi: 10.1073/pnas.87.4.1561
Lazarov, O., Morfini, G. A., Lee, E. B., Farah, M. H., Szodorai, A., Deboer,
S. R., et al. (2005). Axonal transport, amyloid precursor protein, kinesin-
1, and the processing apparatus: revisited. J. Neurosci. 25, 2386–2395. doi:
10.1523/JNEUROSCI.3089-04.2005
Lazarov, O., Morfini, G. A., Pigino, G., Gadadhar, A., Chen, X., Robinson, J., et al.
(2007). Impairments in fast axonal transport and motor neuron deficits in
transgenic mice expressing familial Alzheimer’s disease-linked mutant prese-
nilin 1. J. Neurosci. 27, 7011–7020. doi: 10.1523/JNEUROSCI.4272-06.2007
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402–408. doi: 10.1006/meth.2001.1262
Mann, D. M., Sumpter, P. Q., Davies, C. A., and Yates, P. O. (1987). Glycogen accu-
mulations in the cerebral cortex in Alzheimer’s disease. Acta Neuropathol. 73,
181–184. doi: 10.1007/BF00693786
Minoshima, S., and Cross, D. (2008). In vivo imaging of axonal transport using
MRI: aging and Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl.
1), S89–S92. doi: 10.1007/s00259-007-0707-8
Moreno, H., Yu, E., Pigino, G., Hernandez, A. I., Kim, N., Moreira, J.
E., et al. (2009). Synaptic transmission block by presynaptic injection of
oligomeric amyloid beta. Proc. Natl. Acad. Sci. U.S.A. 106, 5901–5906. doi:
10.1073/pnas.0900944106
Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J., and
Hallbeck, M. (2012). Spreading of neurodegenerative pathology via neuron-
to-neuron transmission of beta-amyloid. J. Neurosci. 32, 8767–8777. doi:
10.1523/JNEUROSCI.0615-12.2012
Ohara, S., Ukita, Y., Ninomiya, H., andOhno, K. (2004). Axonal dystrophy of dorsal
root ganglion sensory neurons in a mouse model of Niemann–Pick disease type
C. Exp. Neurol. 187, 289–298. doi: 10.1016/j.expneurol.2004.03.002
Pierce, J. E., Trojanowski, J. Q., Graham, D. I., Smith, D. H., and McIntosh, T. K.
(1996). Immunohistochemical characterization of alterations in the distribu-
tion of amyloid precursor proteins and beta-amyloid peptide after experimental
brain injury in the rat. J. Neurosci. 16, 1083–1090.
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 139 | 10
Christensen et al. PS1-dependent axonal degeneration in AD mice
Pigino, G., Morfini, G., Atagi, Y., Deshpande, A., Yu, C., Jungbauer, L., et al.
(2009). Disruption of fast axonal transport is a pathogenic mechanism for
intraneuronal amyloid beta. Proc. Natl. Acad. Sci. U.S.A. 106, 5907–5912. doi:
10.1073/pnas.0901229106
Pigino, G., Morfini, G., Pelsman, A., Mattson, M. P., Brady, S. T., and Busciglio,
J. (2003). Alzheimer’s presenilin 1 mutations impair kinesin-based axonal
transport. J. Neurosci. 23, 4499–4508.
Praprotnik, D., Smith, M. A., Richey, P. L., Vinters, H. V., and Perry, G. (1996).
Filament heterogeneity within the dystrophic neurites of senile plaques suggests
blockage of fast axonal transport in Alzheimer’s disease. Acta Neuropathol. 91,
226–235. doi: 10.1007/s004010050420
Roy, S., Zhang, B., Lee, V. M., and Trojanowski, J. Q. (2005). Axonal transport
defects: a common theme in neurodegenerative diseases. Acta Neuropathol. 109,
5–13. doi: 10.1007/s00401-004-0952-x
Salehi, A., Delcroix, J. D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., et al.
(2006). Increased app expression in a mouse model of down’s syndrome dis-
rupts NGF transport and causes cholinergic neuron degeneration. Neuron 51,
29–42. doi: 10.1016/j.neuron.2006.05.022
Salehi, A., Delcroix, J. D., and Mobley, W. C. (2003). Traffic at the intersection
of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 26,
73–80. doi: 10.1016/S0166-2236(02)00038-3
Selkoe, D. J. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.
81, 741–766.
Shin, R. W., Ogino, K., Shimabuku, A., Taki, T., Nakashima, H., Ishihara, T.,
et al. (2007). Amyloid precursor protein cytoplasmic domain with phospho-
Thr668 accumulates in Alzheimer’s disease and its transgenic models: a role
to mediate interaction of Abeta and tau. Acta Neuropathol. 113, 627–636. doi:
10.1007/s00401-007-0211-z
Smith, D. H., Meaney, D. F., and Shull, W. H. (2003). Diffuse axonal injury in
head trauma. J. Head Trauma Rehabil. 18, 307–316. doi: 10.1097/00001199-
200307000-00003
Smith, K. D., Kallhoff, V., Zheng, H., and Pautler, R. G. (2007). In vivo axonal trans-
port rates decrease in a mouse model of Alzheimer’s disease. Neuroimage 35,
1401–1408. doi: 10.1016/j.neuroimage.2007.01.046
St. George-Hyslop, P. H. (2000). Molecular genetics of Alzheimer’s disease. Biol.
Psychiatry 47, 183–199. doi: 10.1016/S0006-3223(99)00301-7
Stokin, G. B., Almenar-Queralt, A., Gunawardena, S., Rodrigues, E. M., Falzone,
T., Kim, J., et al. (2008). Amyloid precursor protein-induced axonopathies are
independent of amyloid-beta peptides. Hum. Mol. Genet. 17, 3474–3486. doi:
10.1093/hmg/ddn240
Stokin, G. B., and Goldstein, L. S. (2006). Axonal transport and Alzheimer’s
disease. Annu. Rev. Biochem. 75, 607–627. doi: 10.1146/annurev.bioche
m.75.103004.142637
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount,
S. L., et al. (2005). Axonopathy and transport deficits early in the patho-
genesis of Alzheimer’s disease. Science 307, 1282–1288. doi: 10.1126/science.
1105681
Teipel, S. J., Stahl, R., Dietrich, O., Schoenberg, S. O., Perneczky, R., Bokde, A. L.,
et al. (2007). Multivariate network analysis of fiber tract integrity in Alzheimer’s
disease. Neuroimage 34, 985–995. doi: 10.1016/j.neuroimage.2006.07.047
Vossel, K. A., Zhang, K., Brodbeck, J., Daub, A. C., Sharma, P., Finkbeiner, S.,
et al. (2010). Tau reduction prevents Abeta-induced defects in axonal transport.
Science 330, 198. doi: 10.1126/science.1194653
Wang, F.-H., Appelkvist, P., Klason, T., Gissberg, O., Bogstedt, A., Eliason, K., et al.
(2012). Decreased axonal transport rates in the Tg2576 APP transgenic mouse:
improvement with the gamma-secretase inhibitor MRK-560 as detected by
manganese-enhancedMRI. Eur. J. Neurosci. 36, 3165–3172. doi: 10.1111/j.1460-
9568.2012.08258.x
Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S., and Malinow, R.
(2010). Amyloid beta from axons and dendrites reduces local spine number and
plasticity. Nat. Neurosci. 13, 190–196. doi: 10.1038/nn.2476
Wirths, O., and Bayer, T. A. (2008). Motor impairment in Alzheimer’s disease and
transgenic Alzheimer’s disease mouse models. Genes Brain Behav. 7(Suppl. 1),
1–5. doi: 10.1111/j.1601-183X.2007.00373.x
Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H. U., and Bayer, T.
A. (2009). Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration
and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol.
118, 487–496. doi: 10.1007/s00401-009-0557-5
Wirths, O., Multhaup, G., Czech, C., Feldmann, N., Blanchard, V., Tremp, G., et al.
(2002). Intraneuronal APP/A beta trafficking and plaque formation in beta-
amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 12,
275–286. doi: 10.1111/j.1750-3639.2002.tb00442.x
Wirths, O., Weickert, S., Majtenyi, K., Havas, L., Kahle, P. J., Okochi, M., et al.
(2000). Lewy body variant of Alzheimer’s disease: alpha-synuclein in dystrophic
neurites of Abeta plaques. Neuroreport 11, 3737–3741. doi: 10.1097/00001756-
200011270-00029
Wirths, O., Weis, J., Kayed, R., Saido, T. C., and Bayer, T. A. (2007). Age-
dependent axonal degeneration in an Alzheimer mouse model.Neurobiol. Aging
28, 1689–1699. doi: 10.1016/j.neurobiolaging.2006.07.021
Wirths, O., Weis, J., Szczygielski, J., Multhaup, G., and Bayer, T. A. (2006).
Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer’s disease.
Acta Neuropathol. 111, 312–319. doi: 10.1007/s00401-006-0041-4
Xiao, A. W., He, J., Wang, Q., Luo, Y., Sun, Y., Zhou, Y. P., et al. (2011).
The origin and development of plaques and phosphorylated tau are associ-
ated with axonopathy in Alzheimer’s disease. Neurosci. Bull. 27, 287–299. doi:
10.1007/s12264-011-1736-7
Yagishita, S. (1978). Morphological investigations on axonal swellings and
spheroids in various human diseases. Virchows Arch. A Pathol. Anat. Histol. 378,
181–197. doi: 10.1007/BF00427359
Zhu, X., Moreira, P. I., Smith, M. A., and Perry, G. (2005). Alzheimer’s disease:
an intracellular movement disorder? Trends Mol. Med. 11, 391–393 doi:
10.1016/j.molmed.2005.07.002
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 08 May 2014; accepted: 11 June 2014; published online: 27 June 2014.
Citation: Christensen DZ, Huettenrauch M, Mitkovski M, Pradier L and Wirths O
(2014) Axonal degeneration in an Alzheimer mouse model is PS1 gene dose depen-
dent and linked to intraneuronal Aβ accumulation. Front. Aging Neurosci. 6:139. doi:
10.3389/fnagi.2014.00139
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Christensen, Huettenrauch, Mitkovski, Pradier and Wirths. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the orig-
inal publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 139 | 11
